Bipolar Disorder (Manic Depression) – Pipeline Review, 2024

Bipolar Disorder, also known as Manic Depression, refers to a mental condition that brings extreme mood changes resulting in experiencing periods of low and high moods. The symptoms and severity of bipolar disorder differ from patient to patient. The key symptoms of bipolar disorder include restlessness, excessive happiness, irritability, insomnia, attempting suicide and others. An estimated 2.8% of the U.S. adults suffer from bipolar disorder every year. Previous year prevalence of bipolar disorder among adults was similar for females (2.8%) and males (2.9%).

 According to the Mental Health Foundation, approximately 1 in every 100 people have manic depression at some point in their life with a major proportion of people developing bipolar disorder between 15-19 year of age. The current treatment for bipolar disorder includes the use of mood stabilizers, antidepressants, atypical antipsychotics, and other medications.

Increased efforts are being taken by major pharmaceutical companies to develop a novel treatment for bipolar disorders. For instance; FK949E, a drug which is being studied by Astellas Pharma Inc. for the treatment of bipolar disorder is currently under phase 3 clinical trials for evaluation of its safety and efficacy.

To know how our report can help streamline your business, Speak to Analyst

At present around 70% of the pipeline candidates for Bipolar Disorder (Manic Depression) are in phase 3 and phase 4 stage. Majority of the studies have been sponsored by pharmaceutical companies.

 Report Description

 The report on ‘Bipolar Disorder (Manic Depression) – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bipolar Disorder (Manic Depression). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bipolar Disorder (Manic Depression).

 The report on ‘Bipolar Disorder (Manic Depression) – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

 Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

 Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Bipolar Disorder (Manic Depression)
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Bipolar Disorder (Manic Depression)
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary